350 rub
Journal Technologies of Living Systems №8 for 2012 г.
Article in number:
Analysis of prognostic factors for complications of interstitial radiotherapy in treatment of prostate cancer
Keywords: prostate cancer radiation injuries early late radiation damage brahiterapiya
Authors:
A.Y. Pavlov, A.D. Tsybulsky, P.V. Daсenko, I.A. Albitskiy, A.V. Semin, R.I. Abi-Haidar, A.V. Shestakov
Abstract:
To evaluate the radiation of lower urinary tract complications after brachytherapy microsources I-125 in patients with prostate cancer. The study included 150 patients with prostate cancer in stage T1-T2N0M0 treated in the Federal State Institution «Russian Health Ministry RNTSRR» in the period from 2004 to 20,010 per year. All patients low-dose brachytherapy was performed microsources I-125 to SLM 140 Gy. The causes of complications were divided into groups - the anatomical and functional, mechanical, and dosimetry. The first covers the maximum volume of the prostate gland volume before the manipulation, the maximum rate of urine flow and residual urine volume. The second group included the number of implanted Intrastat and sources, and the group carried dosimetric implant volume, the volume of the 150 and and 100% isodoses, the dose attributable to 90% of the prostate and urethra, the dose to 30% of the urethra and rectum, and source activity. All investigated parameters influence the severity of early radiation complications of lower urinary tract. Number of Intrastat for more than 25 authentically anticipates the emergence of late radiation cystitis, and 50% of the excess of the threshold for V 150% ? IC immediately after brachytherapy.
Pages: 52-56
References
  1. Sylvester J., Blasko J.C., Grimm P., Ragde H. Interstitial implantation techniques in prostate cancer // J. Surg. Oncology. 1997. V. 66. P. 65-75.
  2. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation // Radiotherapy Oncology. 2004. V. 71. P. 29-33.
  3. Ash D., Bottomley D., Al-Qaisieh B., Carey B., Gould K., Henry A. A prospective analysis of long-term quality of life after permanent I-125 brachythrapy for localised prostate cancer // Radiotherapy Oncology. 2007. V. 84. P. 135.
  4. Bottomley D., Ash D., Al-Qaisieh B., et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds // Radiotherapy Oncology 2007. V. 82 P. 46-49.
  5. Brandeis J.M., Litwin M.S., Burnison C.M., Reiter R.E. Quality of life outcomes after brachythrapy for early stage prostate cancer // J. Urology. 2000. V. 163. P. 851-857.
  6. Cesaretti J.A., Kao J., Stone N.N., Stock R. Effect of low doserate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at 7 years of follow-up // BJU Int. 2007. V. 100. P. 362-367.
  7. Henderson A., Ismail A.K.A., Cunningham M.,
    et al.     Toxicity and early biochemical outcomes from 125iodine prostate brachythrapy in the UK. A prospective study // Clinical Oncology. 2004. V. 16.  P. 95-104.
  8. Merrick G.S., Wallner K.E., Butler W.M. Minimizing prostate brachytherapy-related morbidity // Urology 2003. V. 62. P. 786-792.
  9. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term rectal function after permanent prostate brachythrapy // Cancer journal. 2007. V. 13. P. 95-104.
  10. Miller D.C., Sanda M.G., Dunn R.L., et al. Long term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachythrapy // Journal of Clinical Oncology. 2005. V. 23. P. 2772-27780.
  11. Van Gellekom M.P.R., Moerland M.A., van Vul-
    pen M., Wijrdeman H.K., Battermann J.J.     Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry // Journal of Radiation Oncology and Biological Physics. 2005. V. 63. P. 772-780.
  12. Allen Z.A., Merrick G.S., Butler W.M., et al. Detailed urethral dosimetry in the evaluation of prostate brachytherapyrelated urinary morbidity // Journal of Radiation Oncology and Biological Physics. 2005. V. 62. P. 981-987.
  13. Williams S.G., Millar J.L., Duchesne G.M.,
    Dally M.J., Royce P.L., Snow R.M.     Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy // Radiotherapy oncology. 2004. V. 73. P. 33-38.
  14. Gelblum D., Potters L., Ashley R., Waldbaum R., Wang X.H., Leibel S. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation // Radiation Oncology and Biological Physics. 1999. V. 45. P. 59-67.
  15. Barry M.J., Fowler F.J., O-Leary M.P. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association // Journal of Urology. 1992. V. 148. P. 1549-1557.
  16. Steggerda M.J., van der Poel H.G., Moonen L.M.F. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors // Radiotherapy oncology. 2008 V. 88. P. 108-114.